Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose everolimus plus low-dose tacrolimus after alemtuzumab induction in lung transplantation
2018-001680-24Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Jun 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of everolimus and tacrolimus in Lung allograft rejection (LAR) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: eGFR at two years after transplantation. Started Jun 2018; status: completed.
02
Drugs
everolimustacrolimus
03
Conditions
Lung allograft rejection (LAR)
Beyond the preview
Go deeper on 2018-001680-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001680-24.